Structure via PubChem · Public domain (PubChem)
Ritlecitinib
Sign in to saveRitlecitinib, sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata (hair loss). Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.
Chemical data
- Formula
- C15H19N5O
- Molecular weight
- 285.34 g/mol
- IUPAC name
- 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
- SMILES
- C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
- InChIKey
- CBRJPFGIXUFMTM-WDEREUQCSA-N
- XLogP
- 2.1
- Polar surface area
- 73.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2023
- Admin. routes
- oral
- Indications
- Crohn's disease, rheumatoid arthritis, ulcerative colitis, alopecia areata
via ChEMBL · EBI
Clinical Trials
31 registered- PHASE1COMPLETEDA Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of AgePfizer · NCT05650333
- PHASE1COMPLETEDA Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy AdultsPfizer · NCT06172348
- PHASE1COMPLETEDA Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without FoodPfizer · NCT06369454
- PHASE2COMPLETEDDouble Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in RemissionMassachusetts General Hospital · NCT05636293
- PHASE3COMPLETEDLong-Term PF-06651600 for the Treatment of Alopecia AreataPfizer · NCT04006457
- PHASE2COMPLETEDRitlecitinib for Cicatricial AlopeciaEmma Guttman · NCT05549934
Wikidata facts
- Instance of
- medication
- Mass
- 285.351
- Image
- Ritlecitinib.svg
Show 3 more facts
- isomeric SMILES
- C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
- chemical formula
- C₁₅H₁₉N₅O
- therapeutic area
- alopecia areata
via Wikidata · CC0
~2 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- Economics
- References
- Further reading
- External links
Ritlecitinib, sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata (hair loss). Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.
The most common side effects include headache, diarrhea, acne, rashes, eczema, fever, mouth ulcers, dizziness, shingles rash, and abnormal findings in some laboratory test results.
Excerpted from Wikipedia’s “Ritlecitinib” article, available under the CC BY-SA 4.0 licence.